Psoriasis is a common chronic inflammatory skin condition. It can cause red, purple, or grayish patches to develop that are covered in silvery scales. There are numerous types of psoriasis, and knowing which type a person has allows medical professionals to develop a treatment plan. Psoriasis is not contagious.
Psoriasis is a common condition that affects over 8 million people in the United States.
There are a number of types of psoriasis, and they often have similar triggers. These triggers can include:
This article will discuss different types of psoriasis. For each one, it will list symptoms, locations, and treatment options.
Plaque psoriasis is the most common type of psoriasis.
Symptoms of plaque psoriasis include:
On light skin, these plaques appear as raised and red. On dark skin, the patches may be purple, grayish, or darker brown in color.
These plaques become covered in a silvery or white buildup of dead skin cells that medical professionals call scales.
See pictures of plaque psoriasis here.
Plaque psoriasis can appear on most areas of the body. However, it most often develops on the:
Topical treatments for plaque psoriasis include:
Other treatments can include phototherapy, biologics, and systemic medications that a person can take orally or via an injection.
Learn more about plaque psoriasis here.
Approximately 8% of people who have psoriasis develop guttate psoriasis. This type of psoriasis can start at any age, but it most commonly starts at an early age, around childhood and young adulthood.
Infections of streptococcal bacteria cause strep throat, which is the most common cause of guttate psoriasis.
Guttate psoriasis is a distinct type of psoriasis that appears as small round spots called papules. These are raised and are sometimes scaly.
Inflammation of the skin causes the papules to form. They often appear on the:
However, papules may also develop on a persons face, ears, and scalp.
The first line of treatment for mild guttate psoriasis is topical corticosteroids. Other treatment options include phototherapy and oral treatments.
If a persons symptoms persist, a medical professional may recommend the use of a biologic or a combination of treatments.
Learn more about guttate psoriasis here.
Inverse psoriasis, sometimes called intertriginous psoriasis, affects 2130% of people with psoriasis.
Inverse psoriasis has similar triggers to plaque psoriasis, including:
Inverse psoriasis appears as lesions on the body. These lesions are purple or brown on dark skin, and bright red on light skin.
The lesions may also appear smooth and shiny. However, they tend to lack the scaling that people may notice with plaque psoriasis.
This type of psoriasis commonly develops in the folds of the skin. It most often affects the following parts and areas of the body:
Moisture, rubbing, and sweating can all make inverse psoriasis symptoms worse.
Treatment for inverse psoriasis can include:
Learn more about inverse psoriasis here.
Erythrodermic psoriasis is a rare type of psoriasis that is aggressive and can affect the entire body. It can also become very serious and may be life threatening. It affects 12.25% of people with psoriasis.
This type of the condition has the same general triggers as most other types, including medications, skin injuries, allergic reactions, and stress.
Symptoms of this type of psoriasis can be very serious and include:
If a person experiences these symptoms, they should seek emergency medical attention.
Erythrodermic psoriasis disrupts a persons body temperature and fluid balance. This can cause shivering episodes and swelling due to fluid retention.
A person with this type of psoriasis may also be at a higher risk of infection, pneumonia, and heart failure.
Before treating erythrodermic psoriasis, doctors will first ensure a person is stable. They will start by correcting any fluid, protein, or electrolyte imbalance. They will then treat any secondary infections and protect the person against hypothermia.
An individual with this type of psoriasis can also develop sepsis, which can become fatal, so doctors will treat this immediately if it is present.
Once a persons condition is stable, doctors can treat the erythrodermic psoriasis. They do this using a number of medications, such as cyclosporine, infliximab, methotrexate, or acitretin.
Other treatment options may include topical treatments and biologics that can work alongside the medications described above.
Learn more about erythrodermic psoriasis here.
There are different types of pustular psoriasis, and medical experts categorize them based on where the symptoms appear.
Pustular psoriasis appears as pus-filled bumps called pustules. These pustules might be surrounded by inflamed, discolored skin.
Generalized pustular psoriasis (GPP) causes widespread pustules to appear in large numbers across large areas of the body.
GPP can develop quickly and can be very serious. Its symptoms can also include fever, chills, severe itching, fatigue, a change in heart rate, and muscle weakness.
If a person suspects they have GPP, they should contact a medical professional right away.
Localized pustular psoriasis, also known as palmoplantar pustular psoriasis, tends to affect the palms of the hands and the soles of the feet.
Acropustulosis affects only the tips of the fingers and the toes. This is very rare and may come after an injury or infection.
Learn more about palmoplantar psoriasis here.
Medical professionals will treat this condition with one of the following:
Learn more about pustular psoriasis here.
Nail psoriasis affects the fingernails and toenails. It causes changes in them that can lead to discoloration or alterations in the nail bed.
Common symptoms of nail psoriasis include:
Treatment options for nail psoriasis include:
Learn more about nail psoriasis here.
Psoriatic arthritis is a chronic autoimmune condition that causes the joints to become inflamed. It often occurs with another form of psoriasis.
It can start at any age. However, it most commonly occurs in people aged 3050 years.
Symptoms of psoriatic arthritis include:
This condition can affect small or large joints. In some rarer instances, it can affect the spine.
Early, aggressive treatment can improve the quality of life of a person with psoriatic arthritis. A person with this condition may need to seek treatment from a primary care doctor, a dermatologist, and a rheumatologist.
Treatment for psoriatic arthritis can include oral medications that reduce inflammation and swelling.
A doctor may also use biologics to target specific parts of the immune system to combat symptoms and slow joint damage.
Learn more about psoriatic arthritis here.
Psoriasis is a common skin condition that causes colored patches of skin to develop. These patches can be red, purple, or grayish, depending on a persons skin tone. They can also be covered in scales and become itchy and may cause a burning sensation to develop.
There are various types of psoriasis, all of which produce differing symptoms.
Psoriasis can develop all over the body and can affect the scalp, knees, elbows, torso, genitals, face, hands, feet, or fingernails.
There are numerous treatments for psoriasis, including topical treatments, phototherapy, biologics, and systemic medications.
A person should contact a primary care doctor or dermatologist if they suspect they have psoriasis.
Read the original here:
Types of psoriasis: Pictures, locations, and more - Medical News Today
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]